Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 7/2002

01-09-2002 | Original Article

Suppression of in vivo tumorigenicity of rat hepatoma cell line KDH-8 cells by soluble TGF-β receptor type II

Authors: Wenli Zhao, Masonobu Kobayashi, Wei Ding, Lan Yuan, Prem Seth, Santoso Cornain, Jingxin Wang, Futoshi Okada, Masuo Hosokawa

Published in: Cancer Immunology, Immunotherapy | Issue 7/2002

Login to get access
Metadata
Title
Suppression of in vivo tumorigenicity of rat hepatoma cell line KDH-8 cells by soluble TGF-β receptor type II
Authors
Wenli Zhao
Masonobu Kobayashi
Wei Ding
Lan Yuan
Prem Seth
Santoso Cornain
Jingxin Wang
Futoshi Okada
Masuo Hosokawa
Publication date
01-09-2002
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 7/2002
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-002-0290-6

Other articles of this Issue 7/2002

Cancer Immunology, Immunotherapy 7/2002 Go to the issue

Syposium Series

14th Pezcoller Symposium: The Novel Dichotomy of Immune Interactions with Tumors 30 May–1 June 2002, Trento, Italy

Position Paper

Immunotherapeutic potential of whole tumour cells

Original Article

Cell fusion: an approach to generating constitutively proliferating human tumor antigen-presenting cells

Original Article

Protein A-induced apoptosis of cancer cells is effected by soluble immune mediators

Original Article

Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21

Original Article

Anti-tumor activities of the angiogenesis inhibitors interferon-inducible protein-10 and the calreticulin fragment vasostatin
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits